Abstract 2644: AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models

In non-small cell lung cancer (NSCLC), multiple classes of activating mutations have been identified in EGFR and HER2 that vary widely in their sensitivity to available tyrosine kinase inhibitors (TKIs). Erlotinib, gefitinib, and afatinib are approved for use in patients with the most common forms o...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2016-07, Vol.76 (14_Supplement), p.2644-2644
Hauptverfasser:	Gonzalvez, Francois, Zhu, Xiaotian, Huang, Wei-Sheng, Baker, Theresa E., Ning, Yaoyu, Wardwell, Scott D., Nadworny, Sara, Zhang, Sen, Das, Biplab, Gong, Yongjin, Greenfield, Matthew T., Jang, Hyun G., Kohlmann, Anna, Li, Feng, Taslimi, Paul M., Tugnait, Meera, Xu, Yongjin, Ye, Emily Y., Youngsaye, Willmen W., Zech, Stephan G., Zhang, Yun, Zhou, Tianjun, Narasimhan, Narayana I., Dalgarno, David C., Shakespeare, William C., Rivera, Victor M.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!